Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 4
2005 5
2006 7
2007 5
2008 16
2009 17
2010 19
2011 27
2012 30
2013 19
2014 21
2015 23
2016 23
2017 18
2018 11
2019 7
2020 6
2021 8
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review.
Eley T, Bertz R, Hardy H, Burger D. Eley T, et al. Antivir Ther. 2013;18(3):361-75. doi: 10.3851/IMP2473. Epub 2012 Nov 26. Antivir Ther. 2013. PMID: 23676668 Review.
BACKGROUND: For some antiretroviral therapies, drug concentrations are reduced during pregnancy, potentially compromising effective virological suppression. METHODS: Data on atazanavir boosted with ritonavir in pregnancy are reviewed. RESULTS: With standard atazanavir
BACKGROUND: For some antiretroviral therapies, drug concentrations are reduced during pregnancy, potentially compromising effective virologi …
Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Menshawy A, Ismail A, Abushouk AI, Ahmed H, Menshawy E, Elmaraezy A, Gadelkarim M, Abdel-Maboud M, Attia A, Negida A. Menshawy A, et al. Arch Virol. 2017 Aug;162(8):2181-2190. doi: 10.1007/s00705-017-3346-9. Epub 2017 Mar 30. Arch Virol. 2017. PMID: 28361290 Review.
Atazanavir (ATZ) is a well-tolerated protease inhibitor that can be boosted with ritonavir (r) to treat infection with resistant strains of human immunodeficiency virus 1 (HIV-1). ...
Atazanavir (ATZ) is a well-tolerated protease inhibitor that can be boosted with ritonavir (r) to treat infection with resistant stra
Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.
Cure S, Bianic F, Espinas C, Hardy H, Rosenblatt L, Juday T. Cure S, et al. PLoS One. 2015 May 4;10(5):e0124666. doi: 10.1371/journal.pone.0124666. eCollection 2015. PLoS One. 2015. PMID: 25938588 Free PMC article. Review.
The objective of this study was to evaluate the relative impact of atazanavir (ATV)-based regimens on the renal function of adult patients with HIV. ...
The objective of this study was to evaluate the relative impact of atazanavir (ATV)-based regimens on the renal function of adult pat …
Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
Tigabu BM, Agide FD, Mohraz M, Nikfar S. Tigabu BM, et al. Afr Health Sci. 2020 Mar;20(1):91-101. doi: 10.4314/ahs.v20i1.14. Afr Health Sci. 2020. PMID: 33402897 Free PMC article.
METHODS: Clinical trials with a head-to-head comparison of atazanavir/ritonavir and lopinavir/ritonavir in HIV-1 were included. ...CONCLUSION: Atazanavir/ritonavir has a better viral suppression at lower risk of lipid abnormality than lopinavir/ritonavir. ...
METHODS: Clinical trials with a head-to-head comparison of atazanavir/ritonavir and lopinavir/ritonavir in HIV-1 were included. ...CO …
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.
Carey D, Amin J, Boyd M, Petoumenos K, Emery S. Carey D, et al. J Antimicrob Chemother. 2010 Sep;65(9):1878-88. doi: 10.1093/jac/dkq231. Epub 2010 Jun 16. J Antimicrob Chemother. 2010. PMID: 20554568 Review.
OBJECTIVES: To compare lipid profiles in HIV-infected adults receiving atazanavir-based regimens. METHODS: We conducted a systematic review of randomized controlled trials (RCTs) comparing atazanavir or atazanavir/ritonavir with a comparator and evaluated lip …
OBJECTIVES: To compare lipid profiles in HIV-infected adults receiving atazanavir-based regimens. METHODS: We conducted a systematic …
Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe.
Ngara B, Zvada S, Chawana TD, Nhachi CFB, Rusakaniko S. Ngara B, et al. BMC Pharmacol Toxicol. 2021 May 24;22(1):29. doi: 10.1186/s40360-021-00497-8. BMC Pharmacol Toxicol. 2021. PMID: 34030726 Free PMC article. Clinical Trial.
Pharmacokinetic-pharmacodynamic modelling and simulation allows estimation of potency and evaluate strategies improving treatment outcome. The objective of our study is to determine potency of atazanavir in hair, defined as atazanavir level in hair associated with 5 …
Pharmacokinetic-pharmacodynamic modelling and simulation allows estimation of potency and evaluate strategies improving treatment outcome. T …
A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Baril J, Conway B, Giguère P, Ferko N, Hollmann S, Angel JB. Baril J, et al. HIV Med. 2014 May;15(5):301-10. doi: 10.1111/hiv.12118. Epub 2013 Dec 9. HIV Med. 2014. PMID: 24314017 Free article. Review.
OBJECTIVES: Treatment simplification involving induction with a ritonavir (RTV)-boosted protease inhibitor (PI) replaced by a nonboosted PI (i.e. atazanavir) has been shown to be a viable option for long-term antiretroviral therapy. ...Findings were similar in a subanalysi …
OBJECTIVES: Treatment simplification involving induction with a ritonavir (RTV)-boosted protease inhibitor (PI) replaced by a nonboosted PI …
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Kalantari S, Fard SR, Maleki D, Taher MT, Yassin Z, Alimohamadi Y, Minaeian S. Kalantari S, et al. J Med Virol. 2021 Dec;93(12):6557-6565. doi: 10.1002/jmv.27195. Epub 2021 Jul 28. J Med Virol. 2021. PMID: 34255369 Free PMC article. Clinical Trial.
The purpose of this study was to compare the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients based on clinical and laboratory parameters. ...Patients were randomly assi …
The purpose of this study was to compare the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Rito …
Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study.
Srichatrapimuk S, Wongsa A, Sungkanuparph S, Kiertiburanakul S, Tassaneetrithep B, Phuphuakrat A. Srichatrapimuk S, et al. AIDS Res Ther. 2023 Feb 27;20(1):13. doi: 10.1186/s12981-023-00506-2. AIDS Res Ther. 2023. PMID: 36849967 Free PMC article. Clinical Trial.
METHODS: A randomized, double-blind, crossover study was conducted in HIV-infected persons with dyslipidemia and receiving atazanavir/ritonavir (ATV/r) to evaluate the effect of 2 mg/day pitavastatin treatment versus placebo. ...
METHODS: A randomized, double-blind, crossover study was conducted in HIV-infected persons with dyslipidemia and receiving atazanavir
Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
Iwamoto M, Wenning LA, Mistry GC, Petry AS, Liou SY, Ghosh K, Breidinger S, Azrolan N, Gutierrez MJ, Bridson WE, Stone JA, Gottesdiener KM, Wagner JA. Iwamoto M, et al. Clin Infect Dis. 2008 Jul 1;47(1):137-40. doi: 10.1086/588794. Clin Infect Dis. 2008. PMID: 18513146 Clinical Trial.
Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir....
Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir
243 results